Phase 3 N=325 An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Early Alzheimer's Disease
Primary: Primary Cognitive Efficacy Endpoint (ADAS-Cog13) — 4.40; 3.89 Score on a scale — p=0.6058
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=61 Dementia Risk and Dynamic Response to Exercise
Alzheimer Disease 2 Due to Apoe4 Isoform · Healthy Aging
Primary: Cerebral Blood Flow Area Under Curve — 715; 751 mL/100g tissue
N/A N=159 Cardiorespiratory Fitness, Apolipoprotein E Genotype, and Cognitive Functions: A Prospective Study
Aging · Cognitive Change
Primary: Changes in Inhibitory Performance: Stroop Task — 1.66; -29.85; 21.49; -20.13 ms
Phase 4 N=199 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
Alzheimer's Disease
Primary: CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease) — 8.28; 7.31; 17.86; 10.62 Units on Scale
N/A N=114 Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Mild Cognitive Impairment
Primary: Geriatric Depression Scale — 2.6; 2.1; 2.8; 1.9 score on a scale
Phase 3 N=131 Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
Alzheimer's Disease
Primary: Regional Cerebral Blood Flow Using Arterial Spin-labeling MRI — 55.7; 54.5 mL/g/min — p=0.17
N/A N=30 Triglyceride Effects on Blood Flow in the Human Brain
Alzheimer Disease
Primary: Cerebral Blood Flow Global — -2.2 ml/100g/min — p=.002
N/A N=33 Memory Consolidation in Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Overnight Change in Declarative Memory Performance — 11.2; 6.5 percent change in performance
N/A N=119 Exercise for Brain Health in the Fight Against Alzheimer's Disease
Healthy Cognition
Primary: Rey Auditory Verbal Learning Test Sum of Trials 1-5 — 49.7; 47.6; 51.6; 49.4 Sum of words recalled Trials 1 to 5
N/A N=290 REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
Alzheimer Disease
Primary: Center for Epidemiological Studies-Depression Scale (CES-D) — 4.8; 7.0; 6.4; 5.5 score on a scale
Phase 4 N=89 Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease
Genetic Risk for Alzheimer's Disease
Primary: Change in BOLD Response From Baseline to 24 Weeks During Functional Magnetic Resonance Imaging - Left Posterior Cingulate BOLD Signal at 24 Weeks, Adjusting for Baseline…
Phase 4 N=49 EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
Macular Degeneration · Wet Macular Degeneration
Primary: Anatomic Response
Phase 2 N=7 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
Frontotemporal Lobar Degeneration (FTLD) · Frontotemporal Dementia (FTD) · Tauopathies
Primary: SUVR of 18F-AV-1451 — 1.07; 1.26; 1.03; 1.34 standardized uptake value ratio (SUVR)
N/A N=223 Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Macular Degeneration
Primary: Age in Study Participants — 70.6; 77.8 years
N/A N=68 The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism
Atherosclerosis · Low-density Lipoproteins Aggregation Susceptibility · Low-density Lipoprotein Lipid Composition
Primary: LDL Aggregation Susceptibility — 111.3; 113.1 Minutes
N/A N=160 Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
Late Onset Alzheimer Disease
Primary: Relationship Between Cognitive Change Over Time and Amyloid (Aβ) Deposition — 41; 75 Participants — p=0.02
Phase 3 N=1,974 Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Dyslipidemia
Primary: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score — 0.1206; 0.1134 Z score
Phase 2 N=36 Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Primary: Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance…
Phase 2 N=114 Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
Alzheimer Disease
Primary: Annualized Rate of Change in Tau Burden — 0.0124; 0.0254 SUVR per year — p=0.1953
N/A N=57 The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux
Lipid Metabolism Disorders
Primary: Cholesterol Efflux Capacity (CEC) — 1.30; 0.65 Ratio
Phase 1 N=49 Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
Alzheimer's Disease · Central Nervous System Diseases
Primary: Safety and Tolerability of Multiple Doses of EVP-6124 or Placebo in Subjects With Alzheimer's Disease — 0; 0; 0; 0 Participants
Phase 1 N=145 Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
Alzheimer Disease
Primary: Regional SUVR Value for 18F-MK-6240 — 1.27 SUVR
N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
Phase 2 N=189 Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction
Postoperative Delirium · Postoperative Cognitive Dysfunction
Primary: Number of Adverse Events (AEs) of Grade II or Higher Per Patient — 1; 2 events per participant — p=0.025
Phase 2 N=26 Network-Level Mechanisms for Preclinical Alzheimer's Disease Development
APOE 4
Primary: Functional Connectivity Strengths of Neural Networks — 0.233; 0.318 Pearson coefficient — p=0.007567
N/A N=57 Personalized Nutrition in Young Adults: The Ability of Genetic Information to Motivate Changes in Omega-3 Consumption
Health Behaviour · Nutrition Intervention · Impaired Health
Primary: Omega-3 Dietary Intake — 190.16; 211.50; 395.82; 323.23 mg/day
N/A N=10 tACS for Amyloid-β Reduction in Alzheimer's Disease
Alzheimer Disease
Primary: Change in Amyloid Burden — -1.55 dSUVR
N/A N=10 Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials
Alzheimer Disease
Primary: Percentage of Adherence to Daily Device Use — 95.55; 95.37 percentage of adherence to treatment
Phase 2 N=8 A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
Alzheimer Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 4; 1; 8; 4 Participants
N/A N=20 SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
Mild Cognitive Impairment · Healthy Aging
Primary: Comprehension/Recall of Results - Personal Information Score - PARTICIPANT — 82.40; 94.60; 69.40; 90.80 percentage correct